Breast cancer has an extremely high incidence in women, and its morbidity and mortality
rank first among female tumors. With the increasing development of medicine today, the …

Simple Summary Gene expression signatures were initially developed to take into account
tumor biology for adjuvant chemotherapy decision and have become a standard option in …

This exploratory analysis of the Neoadjuvant Carboplatin in Triple Negative Breast Cancer
(NACATRINE) study aimed to identify the biomarkers of pathological complete response …

Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer
subtype, associated with early metastasis and recurrence as well as poor patient outcome …

Background While the efficacy of neoadjuvant chemotherapy (NACT) in treating triple-
negative breast cancer (TNBC) is generally accepted, not all patients derive benefit from this …

Breast cancer is the most common type of cancer in women besides basal cell and
squamous cell skin cancer. The current systemic therapy guidelines for this heterogeneous …

Simple Summary This study aimed to identify genes associated with neoadjuvant
chemotherapy (NAC) response and disease-free survival (DFS) of triple-negative breast …

Background Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with
clinical outcome in breast cancer (BC). We analyzed the association of dNLR with …

PURPOSE Achieving a pathological complete response (pCR) to neoadjuvant
chemotherapy (NAC) is associated with improved patient outcomes in triple-negative breast …

Objective. A case‐control study was adopted to investigate the efficacy and side effects of
irinotecan combined with nedaplatin (NP) versus paclitaxel combined with cisplatin for …